Search

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

39.04 0.51

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

37.86

Max

39.35

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.4M

-111M

EPS

-1.11

Werknemers

358

EBITDA

420K

-111M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+83.17% upside

Dividenden

By Acuity

Volgende Winsten

2 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.2B

3.8B

Vorige openingsprijs

38.53

Vorige sluitingsprijs

39.04

Nieuwssentiment

By Acuity

75%

25%

295 / 339 Rangschikking in Healthcare

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 sep 2026, 20:07 UTC

News

Xenon Pharmaceuticals Inc is advancing slightly higher, following its announcement to present at the TD Cowen Summit on September 23, 2026.

21 sep 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares fell amid analyst target cuts, with Baird lowering its target to $90 and Needham reducing it to $60, while enrollment in trials is paused.

18 sep 2026, 23:06 UTC

Xenon Pharmaceuticals Inc is up in after-market trading, buoyed by broader market trends despite ongoing concerns over industrial sector weakness and rising Treasury yields.

17 sep 2026, 23:01 UTC

Social Media
News

Xenon Pharmaceuticals submits a New Drug Application for azetukalner but pauses new patient enrollment in other studies, leading to a significant decline in after-hours trading.

16 sep 2026, 20:10 UTC

Xenon Pharmaceuticals Inc is advancing modestly in Wednesday's market session, despite earlier pulling back from a session high amid a broadly lower market.

15 sep 2026, 20:02 UTC

Xenon Pharmaceuticals shares are lower amid broader market declines linked to a significant drop in the NY Empire State Manufacturing Index for September.

14 sep 2026, 22:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, recovering from recent declines despite remaining below the 20-day moving average. No specific news was identified.

11 sep 2026, 20:08 UTC

Xenon Pharmaceuticals Inc shares are lower, marking six consecutive sessions of declines. Broader market sentiment may be affected by a rise in the Consumer Price Index.

9 sep 2026, 20:07 UTC

Xenon Pharmaceuticals Inc. shares are lower today, marking the fourth consecutive session of declines, with no specific news identified for the drop.

8 sep 2026, 20:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours amid a broader market decline, with no specific company news identified for the drop.

4 sep 2026, 23:40 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite no specific company news, amid broader macroeconomic influences.

1 sep 2026, 20:09 UTC

News

Xenon Pharmaceuticals shares are lower as negative sentiment follows an insider sale of 7,068 shares by Chief Medical Officer Kenney Christopher John.

31 aug 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting an upward move since Monday's close amid broader market expectations for interest rate hikes.

28 aug 2026, 20:02 UTC

News

Xenon Pharmaceuticals shares are lower as the company presented Phase 3 data on azetukalner at the European Epilepsy Congress, amid market volatility.

27 aug 2026, 20:02 UTC

Social Media
Event
News

Xenon Pharmaceuticals will present Phase 3 X-TOLE2 trial data at an epilepsy meeting. Shares are lower despite recent announcements regarding upcoming presentations.

26 aug 2026, 21:51 UTC

News

Xenon Pharmaceuticals will present data on azetukalner at the European Epilepsy Congress in September 2026, contributing to shares moving higher in after-market hours.

24 aug 2026, 19:56 UTC

Xenon Pharmaceuticals Inc shares are lower today, reflecting ongoing market weakness. The stock is near the lower end of its one-month range.

21 aug 2026, 23:51 UTC

Xenon Pharmaceuticals shares are lower in after-market trading, reflecting challenges in maintaining upward momentum and positioning below the 20-day moving average.

20 aug 2026, 22:51 UTC

Shares of Xenon Pharmaceuticals are lower in after-market trading, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

19 aug 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is higher in after-market trading, rebounding from an initial dip and reflecting strength despite no specific news to explain the movement.

18 aug 2026, 19:26 UTC

Xenon Pharmaceuticals is trading higher today, reflecting cumulative gains since Monday, though it remains below its 20-day moving average.

17 aug 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is trading higher in after-market hours, despite no specific news to explain the move. The stock remains below its 20-day moving average.

15 aug 2026, 00:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, though no specific news was identified to explain the movement.

14 aug 2026, 23:01 UTC

Xenon Pharmaceuticals shares are higher in after-market hours, reflecting a modest gain since Friday's close. The stock remains below its 20-day moving average.

13 aug 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are declining, trading below their 20-day moving average amid broader market support, despite rising initial jobless claims.

12 aug 2026, 22:51 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, reflecting notable volatility and fluctuations since Wednesday's close within the one-month trading range.

11 aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and subdued trading activity.

10 aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7 aug 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6 aug 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

83.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 71.417 USD  83.17%

Hoogste 90 USD

Laagste 46 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

15

Buy

1

Hold

0

Sell

Sentiment

By Acuity

295 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.